About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

339,504 studies
in
214 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/04/2020.
 Menu
This website is for US healthcare professionals
close-icon

Log In to Bolder Science

logo-iconLog in with Doximity
or
Forgot Password

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

logo-iconLog in with Doximity
or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Specialties

Choose 1 or more specialties that you are interested in:

Subspecialties

You can specify a subspecialty for areas you selected (if available):

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/04/2020.
Previous Next skip
Our Science

    • Enasidenib (IDH2 Inhibitor)

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

    Proposed Mechanism of Action

    Enasidenib is an oral, reversible, selective inhibitor of mutated isocitrate dehydrogenase (IDH) 2.1,2 In vitro studies suggest that the oncometabolite 2-hydroxyglutarate (2-HG), which is present at high levels in patients with IDH mutations,3-5 may drive epigenetic changes that block normal cellular differentiation, leading to a cancerous state.2,4 As demonstrated in preclinical studies, enasidenib binds and inhibits the mutant IDH2 enzyme that is responsible for the accumulation of 2-HG.2

    Enasidenib Hypothesized Mechanism of Action

    Enasidenib is a selective inhibitor of mutant IDH2 and has been hypothesized to reduce 2-HG levels which may restore DNA demethylation in acute myeloid leukemia.

    Enasidenib by Disease State

    Enasidenib in Acute Myeloid Leukemia

    Phase 1
    Newly diagnosed AML with an IDH2 mutation

    Post Approval Research
    Newly diagnosed AML with an IDH2 mutation

    View Trials Investigating Enasidenib in Acute Myeloid Leukemia
    View Rationale for Clinical Development

    Rationale for Clinical Development

    IDH2 mutations occur in various cancers and occur in approximately 8% to 19% of patients with AML.5-7 Preclinical data suggest that enasidenib may have clinical activity in IDH2-mutant AML through the reduction of 2-HG levels and the induction of blast differentiation.2 In vitro studies have shown that enasidenib may reduce 2-HG levels by > 90%, reverse histone and DNA hypermethylation, and induce differentiation in leukemia cell models.2 In a primary human mutant IDH2 AML xenograft model, enasidenib reduced 2-HG levels and induced dose-dependent proliferation and differentiation.2

    View Related Pathways

    Isocitrate Dehydrogenase (IDH) Mutations

    References

    1. Stein EM, et al. Blood. 2014;124 [abstract 115].
    2. Yen K, et al. Blood. 2013;122 [abstract 240].
    3. Ward PS, et al. Cancer Cell. 2010;17:225-234. PMID: 20171147
    4. Gross S, et al. J Exp Med. 2010;207:339-344. PMID: 20142433
    5. Losman JA, Kaelin WG Jr. Genes Dev. 2013;27:836-852. PMID: 23630074
    6. Green CL, et al. Blood. 2011;118:409-412. PMID: 21596855
    7. Im AP, et al. Leukemia. 2014;28:1774-1783. PMID: 24699305